In late December, the ACR convened a COVID-19 Vaccine Consortium via a conference call to consider rheumatology’s place in the massive worldwide effort to develop, test, deliver and further study the vaccines promising to bring the historic pandemic under control.
New Appointments for Carlos Lozada, MD In the midst of the coronavirus pandemic, Carlos J. Lozada, MD, FACP, FACR, professor of clinical medicine, University of Miami Miller School of Medicine, has expanded his professional and volunteer duties. In May he was appointed chief (interim) of the Division of Rheumatology at the Miller School of Medicine,…
Peter Grayson, MD, MSc, a tenure track investigator at the National Institutes of Health (NIH) Intramural Research Program, Bethesda, Md., sometimes wonders how his life would have turned out if the band he was playing in during college had signed a recording contract with a major record label. Dr. Grayson has been playing the piano…
Reactive arthritis is classically associated with an infectious etiology, such as Salmonella, Yersinia, Campylobacter, Chlamydia or gonorrhea. Clostridium difficile is a rare, and recently recognized, causative agent for this condition.1 Case Presentation The patient is a 21-year-old man with a past medical history significant for hereditary spherocytosis and Crohn’s disease, complicated by an anorectal fistula,…
Rheumatology has arguably benefited like no other field from the proliferation of an increasingly effective pipeline of therapeutics. These medications have dramatically raised the bar for clinical outcomes for our patients in a way that we could not have envisioned a short generation ago. With such therapeutic progress now reaching a widening circle of rheumatic…
It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…
As founder and president of a large rheumatology group, Howard M. Busch, DO, says the pandemic has had a limited financial effect on many of the network’s clinics. Communication and technology have been key to adapting to the needs of patients and connecting with other providers during this critical time.
With a new Congress and many new legislators in key leadership positions, your support today will help RheumPAC start the year off strong.
As a new year begins, Government Affairs Committee Chair Blair Solow, MD, takes stock of ACR advocacy wins in 2020 and issues to watch in 2021, including workforce issues, continued telemedicine access, prior authorization relief, Medicare reimbursement and drug pricing.
Is it taboo to talk about politics during the office visit? My morning routine may sound familiar to many of you: I wake up and get ready for work. Before I step out of my car, I put on my mask. I go inside the office to greet the staff and to get my temperature…